Abbott Laboratories (ABT)
Abbott Laboratories reported revenue of $44.33B for the fiscal year ended Dec 31, 2025, up 5.7% from $41.95B the year before. Net income was $6.52B, a net margin of 14.7% (prior year: $13.40B). At the end of that fiscal year the company reported total assets of $86.71B and shareholders' equity of $52.13B.
Revenue
$44.33B
+5.7% vs prior year
Net income
$6.52B
Net margin 14.7%
Diluted EPS
$3.72
USD per share
Total assets
$86.71B
At Dec 31, 2025
Equity
$52.13B
At Dec 31, 2025
Shares outstanding
1,742M
As of Mar 31, 2026
Explore Abbott Laboratories's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Apr 29, 2026
- 10-KFiled Feb 20, 2026
- 10-QFiled Oct 29, 2025
- 10-QFiled Jul 30, 2025
- 10-QFiled Apr 30, 2025
- 10-KFiled Feb 21, 2025
Source: SEC EDGAR XBRL company facts for CIK 1800 (raw data). Most recent filing in this dataset: 10-Q filed Apr 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.